Corvus Pharmaceuticals, Inc. — Director's Dealing 2016

Mar 22, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Corvus Pharmaceuticals, Inc. (CRVS)
CIK: 0001626971
Period of Report: 2016-03-22

Reporting Person: Novo A/S (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$		Common Stock (2130492)		Direct
Series B Preferred Stock	$		Common Stock (356888)		Direct

Footnotes

F1: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") has no expiration date and is convertible at any time at the holder's election. Upon the closing of the Issuer's initial public offering, the Preferred Stock will automatically convert on a one-for-one basis for no additional consideration into common stock.